ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives

Area of Science:

• Rheumatology and Immunology
• Autoimmune Diseases
• Vasculitis Research

Background:

• ANCA-associated vasculitides (AAVs) encompass GPA, EGPA, and MPA, affecting multiple organs.
• Current AAV classification relies on clinical, lab, and basic imaging data from the 1990s.
• Pathogenesis involves small to medium blood vessel inflammation via immunological pathways.

Purpose of the Study:

• To provide an update on the classification, pathogenesis, and treatment of AAVs.
• To review emerging evidence on auto-antibodies, complement, and lymphocyte pathways in AAV.
• To discuss advancements in AAV treatment, including novel therapies and patient-reported outcomes.

Main Methods:

• Review of recent literature on AAV classification, pathogenesis, and treatment.
• Incorporation of updates on newer diagnostic tests like ANCA and advanced imaging.
• Analysis of emerging treatment regimens and patient-reported outcome (PRO) developments.

Main Results:

• Updated classification criteria incorporating ANCA and novel imaging are forthcoming.
• Evidence suggests distinct clinical outcomes and treatment responses based on ANCA subtype (PR3 or MPO).
• Emerging treatments include plasma exchange for severe disease and C5aR inhibitors like Avacopan; PROs are increasingly vital.

Conclusions:

• AAV classification is evolving with new diagnostic tools.
• Understanding immunological pathways is crucial for targeted AAV therapies.
• Novel treatments and patient-centered outcomes are transforming AAV management.